Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance
(2004) In Journal of Viral Hepatitis 11(5). p.459-464- Abstract
- We examined correlates of antinuclear antibody (ANA) positivity (ANA+) in individuals with chronic hepatitis C virus (HCV) infection and the effect of positivity on clinical outcome of HCV. Pretreatment sera from 645 patients from three centres in Sweden (n = 225), the UK (n = 207) and Italy (n = 213) were evaluated by indirect immunofluorescence on Hep-2 cells for ANA pattern and titre by a single laboratory. Liver biopsies were all scored by one pathologist. A total of 258 patients were subsequently treated with interferon monotherapy. There was a significant difference in the prevalence of ANA (1:40) by geographic location: Lund 4.4%, London 8.7%, Padova 10.3% [odds ratio (OR) = 0.66; 95% CI: 0.46-0.94; P = 0.023]. Duration of HCV... (More)
- We examined correlates of antinuclear antibody (ANA) positivity (ANA+) in individuals with chronic hepatitis C virus (HCV) infection and the effect of positivity on clinical outcome of HCV. Pretreatment sera from 645 patients from three centres in Sweden (n = 225), the UK (n = 207) and Italy (n = 213) were evaluated by indirect immunofluorescence on Hep-2 cells for ANA pattern and titre by a single laboratory. Liver biopsies were all scored by one pathologist. A total of 258 patients were subsequently treated with interferon monotherapy. There was a significant difference in the prevalence of ANA (1:40) by geographic location: Lund 4.4%, London 8.7%, Padova 10.3% [odds ratio (OR) = 0.66; 95% CI: 0.46-0.94; P = 0.023]. Duration of HCV infection, age at infection, current age, route of infection, viral genotype, alcohol consumption, fibrosis stage and inflammatory score were not correlated with ANA+ or ANA pattern. Female gender was correlated with ANA+ and this association persisted in multivariable analyses (OR = 3.0; P = 0.002). Increased plasma cells were observed in the liver biopsies of ANA-positive individuals compared with ANA-negative individuals, while a trend towards decreased lymphoid aggregates was observed [hazard ratio (HR) = 9.0, P = 0.037; HR = 0.291, P = 0.118, respectively]. No correlations were observed between ANA positivity and nonresponse to therapy (OR = 1.4; P = 0.513), although ANA+ was correlated with faster rates of liver fibrosis, this was not statistically significant (OR = 1.8; P = 0.1452). Low titre ANA+ should not be a contraindication for interferon treatment. Our observation of increased plasma cells in ANA+ biopsies might suggest B-cell polyclonal activity with a secondary clinical manifestation of increased serum immunoglobulins. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/267727
- author
- Yee, LJ ; Kelleher, P ; Goldin, RD ; Marshall, S ; Thomas, HC ; Alberti, A ; Chiaramonte, M ; Braconier, Jean Henrik LU ; Hall, AJ and Thursz, MR
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- gender, comorbidities, autoimmunity, chronic infections, liver
- in
- Journal of Viral Hepatitis
- volume
- 11
- issue
- 5
- pages
- 459 - 464
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:15357653
- wos:000223820000011
- scopus:5044239483
- ISSN
- 1365-2893
- DOI
- 10.1111/j.1365-2893.2004.00530.x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Infection Medicine (SUS) (013008000)
- id
- 839eb686-1dbb-42c1-b45b-c4b46053a1f9 (old id 267727)
- date added to LUP
- 2016-04-01 12:25:13
- date last changed
- 2022-01-27 03:27:31
@article{839eb686-1dbb-42c1-b45b-c4b46053a1f9,
abstract = {{We examined correlates of antinuclear antibody (ANA) positivity (ANA+) in individuals with chronic hepatitis C virus (HCV) infection and the effect of positivity on clinical outcome of HCV. Pretreatment sera from 645 patients from three centres in Sweden (n = 225), the UK (n = 207) and Italy (n = 213) were evaluated by indirect immunofluorescence on Hep-2 cells for ANA pattern and titre by a single laboratory. Liver biopsies were all scored by one pathologist. A total of 258 patients were subsequently treated with interferon monotherapy. There was a significant difference in the prevalence of ANA (1:40) by geographic location: Lund 4.4%, London 8.7%, Padova 10.3% [odds ratio (OR) = 0.66; 95% CI: 0.46-0.94; P = 0.023]. Duration of HCV infection, age at infection, current age, route of infection, viral genotype, alcohol consumption, fibrosis stage and inflammatory score were not correlated with ANA+ or ANA pattern. Female gender was correlated with ANA+ and this association persisted in multivariable analyses (OR = 3.0; P = 0.002). Increased plasma cells were observed in the liver biopsies of ANA-positive individuals compared with ANA-negative individuals, while a trend towards decreased lymphoid aggregates was observed [hazard ratio (HR) = 9.0, P = 0.037; HR = 0.291, P = 0.118, respectively]. No correlations were observed between ANA positivity and nonresponse to therapy (OR = 1.4; P = 0.513), although ANA+ was correlated with faster rates of liver fibrosis, this was not statistically significant (OR = 1.8; P = 0.1452). Low titre ANA+ should not be a contraindication for interferon treatment. Our observation of increased plasma cells in ANA+ biopsies might suggest B-cell polyclonal activity with a secondary clinical manifestation of increased serum immunoglobulins.}},
author = {{Yee, LJ and Kelleher, P and Goldin, RD and Marshall, S and Thomas, HC and Alberti, A and Chiaramonte, M and Braconier, Jean Henrik and Hall, AJ and Thursz, MR}},
issn = {{1365-2893}},
keywords = {{gender; comorbidities; autoimmunity; chronic infections; liver}},
language = {{eng}},
number = {{5}},
pages = {{459--464}},
publisher = {{Wiley-Blackwell}},
series = {{Journal of Viral Hepatitis}},
title = {{Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance}},
url = {{http://dx.doi.org/10.1111/j.1365-2893.2004.00530.x}},
doi = {{10.1111/j.1365-2893.2004.00530.x}},
volume = {{11}},
year = {{2004}},
}